Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Pheochromocytoma - Pipeline Review, H2 2014

Published: Dec-2014 | Format: PDF | Global Markets Direct | Number of pages: 64 | Code: MRS - 18538


Global Markets Directs, Pheochromocytoma Pipeline Review, H2 2014, provides an overview of the Pheochromocytomas therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pheochromocytoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pheochromocytoma and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

The report provides a snapshot of the global therapeutic landscape of Pheochromocytoma
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Pheochromocytoma and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects
A review of the Pheochromocytoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Pheochromocytoma pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products

Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Pheochromocytoma
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Pheochromocytoma pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Content 

Table of Contents 2
List of Tables 4
List of Figures 4

Introduction 5
Global Markets Direct Report Coverage 5
Pheochromocytoma Overview 6
Therapeutics Development 7
Pipeline Products for Pheochromocytoma - Overview 7
Pipeline Products for Pheochromocytoma - Comparative Analysis 8
Pheochromocytoma - Therapeutics under Development by Companies 9
Pheochromocytoma - Therapeutics under Investigation by Universities/Institutes 10
Pheochromocytoma - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Pheochromocytoma - Products under Development by Companies 13
Pheochromocytoma - Products under Investigation by Universities/Institutes 14
Pheochromocytoma - Companies Involved in Therapeutics Development 15
AstraZeneca PLC 15
Exelixis, Inc. 16
MediaPharma s.r.l. 17
Pfizer Inc. 18
Progenics Pharmaceuticals, Inc. 19
Pheochromocytoma - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 28
cabozantinib s-malate - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
iobenguane sulfate I 131 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
MPHE-001B - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
S-43126 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
sunitinib malate - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
vandetanib - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Pheochromocytoma - Recent Pipeline Updates 46
Pheochromocytoma - Product Development Milestones 60
Featured News & Press Releases 60
Sep 22, 2014: Progenics Pharmaceuticals Presents Long Term Follow-Up of Pivotal Phase 2 Trial of Azedra in Malignant Pheochromocytoma 60
Apr 01, 2014: Progenics Pharmaceuticals and Centre for Probe Development and Commercialization Announce Agreement to Manufacture Targeted Radiotherapeutic Candidate for Ultra-Orphan Indications 60
Nov 25, 2013: Progenics Pharmaceuticals Relaunching Registrational Trial of Azedra to Treat Pheochromocytomas 61

Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 64
Disclaimer 64

List of Tables

Number of Products under Development for Pheochromocytoma, H2 2014 7
Number of Products under Development for Pheochromocytoma - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Products under Investigation by Universities/Institutes, H2 2014 14
Pheochromocytoma - Pipeline by AstraZeneca PLC, H2 2014 15
Pheochromocytoma - Pipeline by Exelixis, Inc., H2 2014 16
Pheochromocytoma - Pipeline by MediaPharma s.r.l., H2 2014 17
Pheochromocytoma - Pipeline by Pfizer Inc., H2 2014 18
Pheochromocytoma - Pipeline by Progenics Pharmaceuticals, Inc., H2 2014 19
Assessment by Monotherapy Products, H2 2014 20
Number of Products by Stage and Target, H2 2014 22
Number of Products by Stage and Mechanism of Action, H2 2014 24
Number of Products by Stage and Route of Administration, H2 2014 26
Number of Products by Stage and Molecule Type, H2 2014 27
Pheochromocytoma Therapeutics - Recent Pipeline Updates, H2 2014 46

List of Figures

Number of Products under Development for Pheochromocytoma, H2 2014 7
Number of Products under Development for Pheochromocytoma - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Products, H2 2014 12
Assessment by Monotherapy Products, H2 2014 20
Number of Products by Top 10 Targets, H2 2014 21
Number of Products by Stage and Top 10 Targets, H2 2014 21
Number of Products by Top 10 Mechanism of Actions, H2 2014 23
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 23
Number of Products by Top 10 Routes of Administration, H2 2014 25
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 25
Number of Products by Stage and Top 10 Molecule Types, H2 2014 27

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing